In association with the researchers at Genentech, Inc., studies conducted by PHAR were a strong presence at the American Thoracic Society Conference (ATS) 2016. One was selected as an oral presentation and three were presented as posters. The study chosen for oral presentation reported on the overall in-hospital mortality, length of stay (LOS), and hospitalization cost in patients with IPF admitted to hospitals in the US, and the posters presented a more in-depth set of data on the mortality and resource utilization of IPF. A study on whether allergic status is associated with increased number of asthma exacerbations was also presented. The posters can be accessed on the PHAR website here.
In response to the rise of effective but expensive new cancer treatments, several organizations have put forth “value frameworks” for oncology. These frameworks, produced by organizations including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Institute for Clinical and Economic Review (ICER), are tools designed to help doctors, patients, and insurance companies determine how much value a treatment provides relative to its cost. Researchers at PHAR, Tufts, UCLA, and Memorial Sloan Kettering Cancer Center, collaborating on the first published evaluation of the reliability of these frameworks, found only fair to good consistency between different individuals using the same framework to evaluate the same drug. They also found that using each of the three different frameworks could lead to significantly different conclusions about the relative value of cancer treatments. These findings suggest it may be premature to use these value frameworks in treatment decision-making without further evidence of their reliability and validity. The study results were presented at the 2016 ASCO meeting.
This retrospective study used insurance claims data to examine the extent of twice-daily use of dornase alfa among cystic fibrosis patients. The study was done in partnership with researchers at Genentech, Inc. and presented at Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting in San Francisco. See the full poster here.
Five studies conducted by teams at PHAR were presented at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting in San Francisco. These studies cover a wide range of diseases and methods including cost effectiveness study of treatments for peripheral t-cell lymphoma, an analysis of insurance claims among cystic fibrosis patients, and an examination of patients with idiopathic pulmonary fibrosis using the National Inpatient Sample. The five posters can be found here.
A study conducted by the researchers at PHAR was selected for oral presentation at Endocrine Society’s 2016 Annual Meeting in Boston in April. The study used data from medical records at 8 US endocrine centers to describe treatment outcomes for Cushing’s Disease patients . The findings of the study can be viewed here. Including this one, there were 5 poster presentations of studies by PHAR. All posters presented at ENDO can be accessed here.
An abstract submitted by researchers at PHAR and Jazz Pharmaceuticals was highlighted by the American Society of Hematology (ASH) at their 57th Annual Meeting. The study estimated the total 100-day and one-year costs associated with inpatient hematopoietic stem cell transplantation, stratified by type of conditioning regimen and other potential contributors to cost. Researchers found that total per patient healthcare costs ranged from $182,000 to $409,000 in the one-year period post transplant. The poster can be accessed here.
For the second year in a row, PHAR was presented with a Silver Medal by the Academy of Managed Care Pharmacy. This year, the award was for a study on health care resource use and costs associated with high OCS use in patients with asthma, conducted by researchers at PHAR and Genentech, Inc., The retrospective claims analysis found that high OCS use was associated with significantly higher costs than no OCS use, especially in patients with possible side effects in the high OCS use cohort. The study can be viewed here.
Carcinoid syndrome describes the hormonal effects of carcinoid tumors, including the secretion of serotonin into the systemic circulation causing episodic diarrhea. Despite the frequent occurrence of this symptom, the healthcare costs and utilization associated with non-infectious diarrhea has not been elucidated. The researchers at PHAR and Novartis Pharmaceuticals Corporation presented their study on the economic impact of Non-Infectious Diarrhea in Patients with Carcinoid Syndrome at the 2015 North American Neuroendocrine Tumor Society’s Annual Symposium. They found that non-infectious diarrhea in newly-diagnosed carcinoid syndrome patients is associated with a significantly increased annual healthcare utilization and an additional $30,000 in total annual healthcare costs. The poster can be viewed here.
The Academy of Managed Care Pharmacy awarded its Silver Medal to a study conducted by PHAR and researchers from Novartis Pharmaceuticals Corporation. This retrospective claims analysis found that the per patient healthcare cost of Cushing’s disease care was more than double the cost for diabetes care and quadruple the cost for population-based controls. The study was presented at the AMCP Nexus Conference in Boston, MA. The poster can be viewed here.
A study completed by PHAR and researchers at bioTheranostics Inc found that use of bioTheranostics’ CancerTYPE ID® molecular test is a cost-effective approach to standardizing diagnostic methods for patients with metastatic tumors of uncertain origin while improving patient care. The study was the first of its kind to examine the implications of molecular classification in standardizing the diagnostic process for metastatic cancer. It was designed to estimate the clinical and economic tradeoffs of using CancerTYPE ID to aid in identifying the primary site of difficult-to-diagnose metastatic cancers and to explore whether the gene assay could be used to standardize the diagnostic process and costs for clinicians, payers, and patients. It was recently published in the Journal of Medical Economics and can be read here. The full press release can be accessed here.